Company news

ACADIA Pharmaceuticals Inc. news in 2021

ACADIA Pharmaceuticals Inc.'s news releases, calls and decks from 2021, newest first.

View company

Acadia Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022

December 21, 2021

Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID® (pimavanserin)

December 19, 2021

Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer

December 13, 2021

Acadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome

December 5, 2021

The Lancet Psychiatry Publishes Results from ADVANCE Study Evaluating Pimavanserin Treatment for Negative Symptoms of Schizophrenia

November 30, 2021

Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms

November 15, 2021

Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 7, 2021

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

November 1, 2021

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

October 31, 2021

Acadia Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 8, 2021

October 26, 2021

Acadia Pharmaceuticals to Present Data on Pimavanserin in Patients with Parkinson’s Disease Dementia with Psychosis from the HARMONY trial at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 24, 2021

Acadia Pharmaceuticals Announces Executive Leadership Change

August 31, 2021

Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

August 4, 2021

Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 3, 2021

The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

July 20, 2021

Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021

July 20, 2021

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)

July 13, 2021

NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders

June 2, 2021

Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results

May 4, 2021

Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021

April 20, 2021

Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

April 4, 2021

Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis

March 7, 2021

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021

Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com

February 18, 2021

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

February 9, 2021

Acadia Pharmaceuticals Announces Commercial Leadership Change

January 26, 2021

Calls in 2021

Decks in 2021